Author information from the last article
Medisinsk avdeling
Drammen sykehus
og
Avdeling for atferdsmedisin
Universitet i Oslo
Forfatterbidrag: idé, design, tolkning, litteratursøk, revisjon og godkjenning av innsendte manusversjon.
John Munkhaugen er ph.d., spesialist i indremedisin og i hjertesykdommer, enhetsoverlege og professor.
Articles by John Munkhaugen
Advance care planning towards the end of life
- Hege Ihle-Hansen,
- Håkon Ihle-Hansen,
- Siri Rostoft,
- John Munkhaugen,
- Siri Færden Westbye,
- Maria Romøren,
- Trygve Johannes Lereim Sævareid,
- Linn Brøderud,
- Karin Berg Hermansen,
- Marie Hamilton Larsen,
- Astrid Klopstad Wahl,
- Marc Ahmed,
- Reidar Pedersen
01.11.2024:
The Norwegian Directorate of Health recently launched national clinical guidelines on advance care planning (ACP) for patients with a short life expectancy (1). ACP is a communication process about the patient's values and wishes for involvement and future treatment and care. Its goal is to ensure...
Frailty, health literacy and self-care in patients admitted with acute heart failure
- John Munkhaugen,
- Elise Sverre,
- Toril Dammen,
- Einar Husebye,
- Erik Gjertsen,
- Oscar Kristiansen,
- Erlend Aune
20.11.2023:
Heart failure is characterised by objective evidence of structural and/or functional cardiac abnormalities that prevent the heart muscle from pumping a sufficient amount of oxygen-rich blood to the body (1). Traditionally, heart failure has been classified into distinct phenotypes (systolic and...
Personalised cardiovascular disease prevention in the new guidelines
- Elise Sverre,
- Sigrun Halvorsen,
- Maja-Lisa Løchen,
- John Munkhaugen
23.11.2022:
The new European Guidelines for cardiovascular disease prevention have introduced a stepwise approach with lifestyle measures at the core. The use of drug treatment is recommended based on a risk assessment also taking into consideration the patient's frailty, comorbidities and own preferences. New...
Statins seldom cause adverse reactions
- John Munkhaugen,
- Oscar Kristiansen,
- Elise Sverre,
- Kjetil Retterstøl,
- Serena Tonstad
21.01.2022:
Statins seldom cause muscle side effects and are tolerated by the great majority of people. It is important to spend time, build trust, manage negative expectations and identify other causes of muscle problems than the use of statins. Statins are cost-effective drugs that cause regression of...
Post-myocardial infarction rehabilitation and secondary prevention in hospitals
- Kari Peersen,
- John Munkhaugen,
- Siv Jorunn Olsen,
- Jan Erik Otterstad,
- Elise Sverre
29.10.2021:
Around 12,000 people suffer myocardial infarction in Norway each year (1), a quarter of whom also had prior coronary artery disease (2). To prevent new events, it is recommended that established cardiovascular risk factors be monitored and treated (3). Data from Norway show that the majority of...
The follow-up after myocardial infarction – is it good enough?
- John Munkhaugen,
- Kari Peersen,
- Elise Sverre,
- Erik Gjertsen,
- Lars Gullestad,
- Toril Dammen,
- Einar Husebye,
- Jan Erik Otterstad
05.03.2018:
The majority of Norwegian coronary patients fail to change their lifestyle behaviour and miss the recommended treatment targets for cholesterol and blood pressure after discharge from hospital. Coronary heart disease is the single most important cause of death in the world, and annually more than 13...
Is the evidence base for post-myocardial infarction beta-blockers outdated?
- Jan Erik Otterstad,
- John Munkhaugen,
- Vidar de Bourg Ruddox,
- Jon Haffner,
- Dag S. Thelle
19.04.2016:
Post-myocardial infarction beta-blocker therapy is based on studies from the early 1980s. Since then, the diagnostics for myocardial infarction have become more sensitive, revascularisation has improved survival and there are now improved secondary prophylaxis drugs. We therefore believe it is time...